Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2019.0286
REVIEW
|
Single-cell genome and transcriptome sequencing and editing technologies enhance understanding of regulatory networks with future clinical implications for breast cancer.
|
Prof. G. Zografos, MD, PhD.
|
| |
Abstract
Rapid progress from bulk NGS to breakthrough combination of single-cell RNA-sequencing and CRISPR-CAS9 system is revolutionizing biomedical research in health.
Particularly in cancer, initial data demonstrate cell-to-cell heterogeneity dependence drug sensitivity represent the most great hope for revolutionizing precision oncology. Moreover, the CRISPR-CAS9 system provides high expectation for the discovery of novel therapeutic targets. The breakthrough of both techniques represents an exciting distant future perspective to breast cancer precision medicine.
(Citation: Gastric & Breast Cancer 2019; 14(1): 83-90)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
